topotecan has been researched along with nsc 366140 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ferguson, DM; Flatten, KS; Gálvez-Peralta, M; Hackbarth, JS; Hiasa, H; Kaufmann, SH; Xing, C | 1 |
Kaufmann, SH; Svingen, PA | 1 |
Bally, M; Hu, Y; Krishan, A; Mayer, LD; Nie, W; Sridhar, KS | 1 |
3 other study(ies) available for topotecan and nsc 366140
Article | Year |
---|---|
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.
Topics: Acridines; Aminacrine; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Humans; Models, Chemical; Neoplasms; RNA, Small Interfering | 2009 |
Immunoblot analysis and band depletion assays.
Topics: Acridines; Antineoplastic Agents; DNA Adducts; DNA Topoisomerases, Type I; Humans; Immunoblotting; K562 Cells; Leukemia; Pyrazoles; Topotecan | 1999 |
Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.
Topics: Acridines; Agar; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catalysis; Cell Line, Tumor; Cell Nucleus; Clinical Trials as Topic; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Superhelical; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Humans; Inhibitory Concentration 50; Pyrazoles; Topotecan | 2004 |